Please use this identifier to cite or link to this item: https://repositorio.ufu.br/handle/123456789/30763
Full metadata record
DC FieldValueLanguage
dc.creatorRamos, Danielle Stephane-
dc.date.accessioned2020-12-22T13:50:11Z-
dc.date.available2020-12-22T13:50:11Z-
dc.date.issued2020-12-10-
dc.identifier.citationRAMOS, Danielle Stephane. Aloimunização eritrocitária em pacientes politransfundidos com doenças onco-hematológicas: uma revisão de literatura. 2020. 36 f. Trabalho de Conclusão de Curso (Graduação em Biomedicina) - Universidade Federal de Uberlândia, 2020.pt_BR
dc.identifier.urihttps://repositorio.ufu.br/handle/123456789/30763-
dc.description.abstractAlloimmunization is caused by exposure to erythrocytes from a donor who expresses antigens from blood groups different from those of the receptor, triggering an immune response of varying degrees. Multi-transfused patients, especially those with oncohematological diseases, are more predisposed to the risk of receiving incompatible blood components and developing alloantibodies. Thus, the objective of this literature review was to assess, which are the most frequent hematological malignance in alloimmunized multitransfused patients, to determine which are the most common erythrocyte antigens and antierythrocyte alloantibodies detected in the population profile of the study, as well as to identify appropriate measures to be taken to minimize alloimmunization rates in this transfusiondependent population. For this purpose, well-defined eligibility criteria were used, and the search took place in the electronic bibliographic database MEDLINE (through PubMed). Based on the criteria used, 10 articles were included to compose this review. It was observed that the most prevalent onco-hematological disease in the studied population was the Myelodysplastic Syndrome, as well as the frequent detection of alloantibodies associated with the Rh, Kell, MNS and Kidd systems. Furthermore, all studies pointed to extensive erythrocyte phenotyping as a way of minimizing alloimmunization rates among patients with hematological malignancies, as well as reducing the risks of occurrence of transfusion hemolytic reactions. Thus, although the reality represented in transfusion medicine is very different between countries, the performance of phenotyping and genotyping to identify systems other than ABO/Rh, especially for chronically transfused patients who have Myelodysplastic Syndrome, can minimize the risk of alloimmunization and its consequences, with positive effects on the safety and efficacy of transfusion therapy.pt_BR
dc.description.sponsorshipPesquisa sem auxílio de agências de fomentopt_BR
dc.languageporpt_BR
dc.publisherUniversidade Federal de Uberlândiapt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectAloimunizaçãopt_BR
dc.subjectDoenças onco-hematológicaspt_BR
dc.subjectPolitransfundidospt_BR
dc.titleAloimunização eritrocitária em pacientes politransfundidos com doenças onco-hematológicas: uma revisão de literaturapt_BR
dc.title.alternativeErythrocyte alloimmunization in multi-transfused patients with hematologic malignancies: a literature reviewpt_BR
dc.typeTrabalho de Conclusão de Cursopt_BR
dc.contributor.advisor-co1Oliveira, Mário Cézar-
dc.contributor.advisor-co1Latteshttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4480695U8&tokenCaptchar=03AGdBq25zo0rriNZlTJNy5CWsfXmQC5Jv5F-4AR0qGgpUxyg5eSjEhwigq0iAJpyaiTZwUpFhOXBQbekSMK4BFcCgY5Y1zyLgdcHBZl4A5NXMrgrjTXPpGiCPBi1seoF_kNxJ62gxpuRuS688isa7teSEcAn2sY1uTC1GW6f1xNw2CcUYMbgteIlOwEOhqiobjIyBEA7Zkacy28sOd9jI2lcTLASVTpMcesni7UXjV3kmRTzPu7uLvBx9u2Cqs5xZhF49TJncz1S9-TR2OLq3xyeMwjueYSXfao8p2CwSda4rN1NCto5FN4WP-wDlXNptqJI7Kr7gnP5l2lk9kuXvitAJjWm9aYpmUzUx-AXYbLGlaHtzbk87y22NBWk0anm0X8yCs2MBLc84wZA5dUlMCMIpFNayJdZzRrgCpkRIBFaUNeMTMlwDoElROH2J1oXE6BLUILceQM302BS_7x2lZs-VUZEu6_FTfn4K0JXjGHXq3_GazLCf3gA2vMD0EJeH53A7K7H7uqE3Xob7HiWH2kAy3dG7b0MiyQpt_BR
dc.contributor.advisor1Royer, Sabrina-
dc.contributor.advisor1Latteshttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4483549D2&tokenCaptchar=03AGdBq26o-SKESa4CWN1L16SRI8368auK5kAE3y6NS_n-w5e9vR1c1hFP---sVlu9mvnDCdwPPSGzyxuHYrsyqUERAXD4Tz7MLNu0TPTT2A_XtR_5ilPGVkqLD60FQV3MtUy8mwOHggTHVP1Wja5akTb1QadHWiYxxZt1UvZCtNj3I8RrOku-gYrTpdt3kW-QcPvEMx91ZiKkQaVV0zmlFIecwKRRIpH2z_DSbbTQM6OokisoniUYEXvhXe-vXQbGwugyT7p9G_8P-33yedIeyorklKLgmP8GmZ-P6vZb8uNAEjv_OXrN-7JI9_aVHq7sat3KS4nhhEuh_SOApa-BVNYpQ1bgvlvZEiElOEWbXwcg4G4svnEHiFTuMZYeER1E63yFlSa7on90srZqHyO2yk5AiQ6lDyxG5G-zZhCLCFLCIyhAgSM72ZJ4C3Jfy3q_2IpEYLhjk-hGu-Mdnze6SiIK39lic2mRG4VIWcbvPtwkoGk3h39ILGdIUFrK7vZF_dqGEeLUtA4AxDgR_ahNg1iSbux8W3Os2wpt_BR
dc.contributor.referee1Royer, Sabrina-
dc.contributor.referee1Latteshttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4483549D2&tokenCaptchar=03AGdBq25VE60fCnRwiwEqoB-C0Un5QN8TdC0Iv8KKj1j2UXEHUnMLVS4XGLqbGy9hW4E9SeU1fOuZF6yptxIcGLSq0XXMAQyAEnssMGzwy02Yh7_UxrTTxLMeHiTrjZj9jov2e21mCxAASeFclLFuB_cuoUh01DxYV2OkIne28z3rrgWSlVLDq5czxZ3VBbJ8XDlV5WVtjjves6RvOUUhJlnh7oHlJQYjKMSzJTtLSaEKGUuXgaTx7qEBbTUqn3OcjimPimyINPBybYxAbstkSz8pLOe_fP0tGV_ya0BGnRiWde3VGnOxpPXbUK6z5x4qO9qaH2BMGaIyZVGLMNH8kPp7dwUIdDp1GC1J0zGImAJ60MiZZ_i2Bhgw6GG5CYZiZzwHYQjcspem6PlzN3A4irsprJsyKZEpQnvndweKhuLVVcMd32xZ7QTBrOS1cyfP645k6Rj1WUr72x9nyeoOQLlEZtNYDhG7ANgNAvQ8jPhjsxkevaB7-2kWacEEXjVScrBv-twSo8A1rRi-3SZvNXFll1j0KHXBJQpt_BR
dc.contributor.referee2Oliveira, Ana Carolina de Morais-
dc.contributor.referee2Latteshttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4248658T7&tokenCaptchar=03AGdBq24LAHSCcaFBKSRNFX1yinL0kWDVWQmwcz9aE6A_OSsseIftv953TjeJma7s7zObTEssiiLV2AbILp95M0SZo7QiMYJGou3DDg-E67-Dtl4PjzH75rnhZR4CKAztG2cS8f7rL7rjGmIjAya405j9ytRpsVFT9pM-7tkEssBusqsA2Ua_16hJXLLlSOI4ZAgDve1O8T1y7jXTWL7XEDHKkay7HdZx8SW6TaMKrpqdvBwCKCEhVqzRyE1hKRGnFlNT5SUNMzgRAUhuiH-SrGTO23dnqMqFcslnA74SyZATq_Uk6fQiVjhT0EmM8FXfe5MkJNmv3XvNEZZnSMH2qHc5cLU8cvXmyQG7pgtljD9dFT5msPDZHFwEJEITqUj9G6SyAhI5SVxcjTN6rFI6O0Sax3GBO0RVu1-v8Xoyb03eQKNNSrylaZ7pevz3NZIslbjUVicP4MrTYR_lvzTLvn349HK8MnPD6T3TZPt20j4evuCF0n_l7OuvSL76aGVlMNkFqb3erYmfXzwNSiPw-fX2-KNyPsVoFApt_BR
dc.contributor.referee3Batistão, Deivid William da Fonseca-
dc.contributor.referee3Latteshttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4550204D3&tokenCaptchar=03AGdBq27YYcrktMla8RiKJSe3HPOlqkiX-NrWu_NFP1OzL0QEbY_pftr0vM9-tMe2QQlmMTa-A0xu019gDxyCxMO_YVZOqoIhNGMvUWz6O4oQRFKZ7PP0my5u-nJM3Gxt8-4cJ768-tSD5yAlKkF7wTmpZwO5qWmxLNjkRgnDkERKO0H8EwN4wnqMimCQmqQ_M2WGG3QowOX_EsKo3_dlwF3_2EQ7drDEr5SWq-hlUM_BeFiKjsA8lKS12lIbQ5tFH3P3OHhJqSMMu4Cnuj1OYCLj8Z9tuwUbBtYESQsfgnHR3_McpsFsuunqC-dDZULLM6cca2JKYnZFKn8jk90tpNY7DIzBds5dpjvzDpuQslzciKrsjEYmERq9NBJda1jzni5oHo6BKGzeXBPoLNE8naMG4mpJg9T4tiA5Fyx1ijUaQz88DVHgLSPUTb7jeqXFJs4opW52UbFo8JtTTUv3j3QyOCIHk1jpB-mpK2TTZcNpXHUrc2vmzvMKwu3-DvMF3yeU-kmFBRun8hXw7e9a0OkQIVhSsJrsPQpt_BR
dc.creator.Latteshttp://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4207506A1&tokenCaptchar=03AGdBq25vGQKFYFm1bgfp8F1inFgzQtnPAAaBngel4WbcIxkk7q5iYHTmxCK4SO5wfSydzBx3Lcs_ynMVUjjoXN2d554pJ8F4E0rdeJsCkiCypuh3Mq7fT49BOzVT_WGhpjpJNa-QpOiUQXgLs6McHFUyezs1jX7RS1y2b3UKXmsb7oh4UnhR0oQwqDegkJlHHVF6FbK7FqUGWZyC0MsqwkcHnlt5vg6_Z11dBKRq0ORXH6iDvzIctCNcuIS4VxSEB-uVmLCAdd4IJyLE6-U5sZ9te4C6dhBDeLI8kzC7prO7E_EBbyo1DlCaMfvRCGSpaqzK33acpT9KfLCeZfhZ9aAaDnsJFuEQrC-NeFWXYPOKTUumiQcOhybArx3F3zgwhNH_lsO9YyZg-PeC0aetwtbp7OOms9tUHaET-GgUjJTcwInA1VjoOHzYg-va1fIYPJ41T_yDEJ-XeSPgDmNEviwEhsJ1lZN9C1bSWiWk9Wuugqf3QElu0PwmRw41u5hwcP71B7TIraXmoGdWphTZe7DM3o34_eHasgpt_BR
dc.description.degreenameTrabalho de Conclusão de Curso (Graduação)pt_BR
dc.description.resumoA aloimunização é causada pela exposição a eritrócitos de um doador que expressa antígenos de grupos sanguíneos diferentes daqueles do receptor, desencadeando uma resposta imune de graus variados. Pacientes politransfundidos, em especial aqueles com doenças oncohematológicas, estão mais predispostos ao risco de receberem hemocomponentes incompatíveis e desenvolverem aloanticorpos. Assim, o objetivo desta revisão de literatura foi avaliar quais são as doenças onco-hematológicas mais frequentes em pacientes politransfundidos aloimunizados, determinar quais são os antígenos eritrocitários e os aloanticorpos antieritrocitários mais comuns detectados no perfil populacional do estudo, assim como identificar medidas adequadas a serem tomadas a fim de minimizar as taxas de aloimunização nesta população dependente de transfusão. Para isto, foram utilizados critérios de elegibilidade bem delineados e a busca ocorreu na base de dados bibliográfica eletrônica MEDLINE (através do PubMed). A partir dos critérios utilizados foram incluídos 10 artigos para compor esta revisão. Observou-se que a doença onco-hematológica mais prevalente na população estudada foi a Síndrome Mielodisplásica e os aloanticorpos detectados com maior frequência foram os associados aos sistemas Rh, Kell, MNS e Kidd. Também, todos os trabalhos apontaram a fenotipagem eritrocitária extensa como forma de minimizar as taxas de aloimunização entre os pacientes com neoplasias hematológicas, assim como reduzir os riscos de ocorrência de reações hemolíticas transfusionais. Dessa forma, embora a realidade retratada na medicina transfusional seja muito distinta entre os países, a realização da fenotipagem e genotipagem para a identificação de outros sistemas além do ABO/Rh, principalmente para os pacientes cronicamente transfundidos e que apresentam Síndrome Mielodisplásica, pode minimizar o risco de aloimunização e suas consequências, com reflexos positivos na segurança e eficácia da terapia transfusional.pt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.courseBiomedicinapt_BR
dc.sizeorduration36pt_BR
dc.subject.cnpqCNPQ::CIENCIAS BIOLOGICASpt_BR
dc.subject.cnpqCNPQ::CIENCIAS DA SAUDEpt_BR
Appears in Collections:TCC - Ciências Biomédicas

Files in This Item:
File Description SizeFormat 
AloimunizaçãoEritrocitáriaEm.pdf646.94 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.